Abstracts tagged "diagnosis and psoriatic arthritis"

Abstract Number: 353 • 2013 ACR/ARHP Annual Meeting
Time Interval Between The Onset Of Psoriasis and The Onset Of Psoriatic Arthritis May Define Disease Subsets
Arane Thavaneswaran¹, Vinod Chandran² and Dafna D. Gladman², ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Psoriatic Arthritis (PsA) is a heterogeneous disease with widely varying clinical features and outcomes. Phenotypic heterogeneity may reflect genetic heterogeneity. We aimed to investigate…
Abstract Number: 1354 • 2012 ACR/ARHP Annual Meeting
The Prevalence of Psoriatic Arthritis Based On Rheumatologists’ Clinical Assessment Before and After Laboratory and Radiographic Tests in Psoriasis Patients in European/North American Dermatology Clinics
Dafna D. Gladman¹, Philip J. Mease², Rafat Y. Faraawi³, Eustratios Bananis⁴, Andrew S. Koenig⁵, Robert Northington⁴, Joanne Fuiman⁴ and Daniel Alvarez⁴, ¹Centre for Prognosis Studies in The Rheumatic Diseases, Toronto Western Research Institute, University of Toronto, University Health Network, Toronto, ON, Canada, ²Division of Rheumatology Research, Swedish Medical Center, Seattle, WA, ³McMaster University, Hamilton, ON, Canada, ⁴Specialty Care, Pfizer Inc., Collegeville, PA, ⁵Specialty Care Business Unit, Pfizer Inc., Collegeville, PA
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease with a heterogeneous presentation that is associated with impaired quality of life, joint damage, and limited…
Abstract Number: 567 • 2012 ACR/ARHP Annual Meeting
Prevalence of Psoriasis and Psoriatic Arthritis in a Northern Population of Spain
Jose Luis Fernandez-Sueiro¹, JA Pinto¹, S. Pertega-Diaz², Manuel Acasuso³ and Ignacio Herrero de Padura⁴, ¹Rheumatology Division, Complejo Hospitalario Universitario La Coruña, La Coruña, Spain, ²Epidemiology and Statistics, Complejo Hospitalario Universitario La Coruña, La Coruña, Spain, ³Centro de Salud San José, Centro de Salud, San José, La Coruña, Spain, ⁴Centro de Salud San Jose, Centro de Salud, San José, La Coruña, Spain
Background/Purpose: There are few data in Spain evaluating the prevalence of psoriasis in the general population, accordingly there are not data evaluating the prevalence of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].